Palatin Technologies, Inc. (PTN)
Stock Price:
$0.387 USD
-0.012 (-3.01%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
88.95M |
| Revenue (ttm) |
117,989 |
| Net Income (ttm) |
-22.43M |
| Shares Out |
229.86M |
| EPS (ttm) |
-0.10 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$0.387 |
| Previous Close |
$0.399 |
| Change ($) |
-0.012 |
| Change (%) |
-3.01% |
| Day's Open |
0.400 |
| Day's Range |
0.387 - 0.410 |
| Day's Volume |
1,383,221 |
| 52-Week Range |
0.355 - 0.899 |
More Stats
| Market Cap |
88.95M |
| Enterprise Value |
7.37M |
| Earnings Date (est) |
Feb 16, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
229.86M |
| Float |
220.74M |
| EPS (basic) |
-0.10 |
| EPS (diluted) |
-0.10 |
| FCF / Share |
0.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
46.39% |
| Payout Ratio |
n/a |
| Shares Short |
9.16M |
| Short Ratio |
7.49 |
| Short % of Float |
4.15% |
| Beta |
1.50 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
2.16 |
| PS Ratio |
753.92 |
| PB Ratio |
1.14 |
| Revenue |
117,989 |
| Operating Income |
-23.61M |
| Net Income |
-22.43M |
| Free Cash Flow |
41.26M |
| Net Cash |
81.59M |
| Net Cash / Share |
0.35 |
| Gross Margin |
-11,731.10% |
| Operating Margin |
-20,007.61% |
| Profit Margin |
-19,006.90% |
| FCF Margin |
34,972.36% |
| ROA |
-15.55% |
| ROE |
-24.82% |
| ROIC |
2,662.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$2.17*
(460.72% upside)
Low
1.50
Current: $0.387
High
3.00
Target: 2.17
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 0.12 | 60.30 | 67.13 | 44.72 | - | 12.95 | - | 0.01 | 0.07 | 1.48 |
| Revenue Growth | -99.8% | -10.18% | 50.11% | - | - | - | - | -85.95% | -95% | - |
| Gross Profit | 0.12 | 60.30 | 67.13 | 44.72 | - | 12.95 | - | 0.01 | 0.07 | 1.48 |
| Operating Income | -23.61 | 35.74 | 25.93 | -10.57 | -49.25 | -17.29 | -15.79 | -15.59 | -18.79 | -13.65 |
| Net Income | -22.43 | 35.77 | 24.70 | -13.33 | -51.71 | -17.67 | -13.93 | -20.86 | -17.25 | -12.82 |
| Shares Outstanding | 235 | 208 | 198 | 184 | 157 | 121 | 107 | 97.62 | 34.90 | 20.08 |
| Earnings Per Share | -0.10 | 0.16 | 0.12 | -0.07 | -0.33 | -0.15 | -0.13 | -0.21 | -0.49 | -0.64 |
| EPS Growth | - | 33.33% | - | - | - | - | - | - | - | - |
| Operating Cash Flow | 41.33 | -21.78 | 1.70 | 12.88 | -47.36 | -13.36 | -12.21 | -13.65 | -15.49 | -11.03 |
| Capital Expenditures | -0.06 | -0.04 | -0.02 | -0.13 | -0.02 | - | -0.01 | -0.05 | 0.48 | 0.01 |
| Free Cash Flow | 41.26 | -21.82 | 1.68 | 12.75 | -47.38 | -13.36 | -12.21 | -13.70 | -15.01 | -11.02 |
| Cash & Equivalents | 82.85 | 43.51 | 38.00 | 40.45 | 9.38 | 27.30 | 12.18 | 24.42 | 4.18 | 19.22 |
| Total Debt | 1.27 | 0.33 | 6.28 | 14.12 | 19.52 | 9.85 | - | 0.02 | 0.04 | 0.08 |
| Net Cash / Debt | 81.59 | 43.18 | 31.72 | 26.33 | -10.14 | 17.45 | 12.18 | 24.40 | 4.14 | 19.14 |
| Assets | 85.05 | 105 | 39.02 | 56.83 | 10.86 | 29.47 | 12.56 | 25.07 | 5.38 | 21.17 |
| Liabilities | 4.88 | 4.19 | 12.05 | 62.00 | 28.44 | 17.27 | 2.77 | 2.10 | 3.55 | 2.98 |
| Book Value | 80.17 | 101 | 26.96 | -5.16 | -17.59 | 12.20 | 9.79 | 22.98 | 1.83 | 18.19 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Palatin Technologies, Inc. |
| Country |
United States |
| Employees |
20 |
| CEO |
Carl Spana |
Stock Information
| Ticker Symbol |
PTN |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: PTN |
| IPO Date |
October 28, 1993 |
Description
Palatin Technologies, a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.